Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1.15 1.10 1.20 1.15 1.15 1.15 3,545 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2.3 -1.0 -0.2 - 8

Deltex Medical Group PLC Results for the year ended 31 December 2021

07/04/2022 7:01am

UK Regulatory (RNS & others)

Deltex Medical (LSE:DEMG)
Historical Stock Chart

From Mar 2022 to Jun 2022

Click Here for more Deltex Medical Charts.


RNS Number : 5512H

Deltex Medical Group PLC

07 April 2022

7 April 2022 - Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, today announces its results for the year ended 31 December 2021.

Deltex Medical Group plc ("Deltex Medical" or the "Group")

Results for the year ended 31 December 2021



-- revenues: GBP2.3 million (2020: GBP2.4 million)

-- International division performed well in 2021 with growth of 40% to GBP0.9 million (2020: GBP0.7 million)

-- gross margin up slightly to 70% (2020: 68%)

-- overheads flat at GBP2.7 million (2020: GBP2.7 million, excluding exceptional items)

-- adjusted EBITDA: GBP(0.5) million (2020: GBP(0.2) million)

-- loss for the year: GBP(1.0) million (2020: GBP(0.8) million)

-- cash at hand (31 December, 2021): GBP0.4 million (2020: GBP0.9 million), before GBP1.4 million (gross) fund raising announced on 8 February 2022


-- during 2021 many of Deltex Medical's principal markets were effectively closed as elective surgical procedures were cancelled around the world due to the pandemic. Elective surgery is now starting to resume globally

-- many hospitals barred access to salespersons and clinical educators for a large proportion of the year, which compounded the sales challenges facing the Group

-- post pandemic, there is now a substantial backlog in elective surgical procedures around the world which represents a significant commercial opportunity for Deltex Medical as its TrueVue Doppler technology has been shown to reduce patient length-of-stay and hence increase hospital throughput / capacity

-- there are now encouraging signs of hospital access improving for our sales teams

-- excellent progress was made in research and product development during 2021, both in the development of our new, next generation monitor which will be launched in 2022 and our new non-invasive Doppler-based haemodynamic monitoring technology which has broader applications within the hospital setting

-- trading in 2022 has started positively including the announcement in January 2022 of a US$0.2 million order from the Americas

Commenting on the results, Nigel Keen, Chairman of Deltex Medical, said:

"2021 was a challenging year for Deltex Medical; however, as the pandemic subsides the prospects for the Group in 2022 are encouraging."

"The size of the backlog in elective surgery around the world creates an opportunity to leverage the benefits of Deltex Medical's technology, particularly in relation to increasing patient throughput and improved outcomes."

"The expected return to normal levels of elective surgery represents a significant commercial opportunity for the Group."

"The launch of our next generation state-of-the-art monitor coupled with our new, easy-to-use non-invasive monitoring device, with its broader applicability throughout the hospital, provides opportunities for the Group to expand its addressable markets."

For further information, please contact:

 Deltex Medical Group plc               01243 774 837 
  Nigel Keen, Chairman          
  Andy Mears, Chief Executive 
  Natalie Wettler, Group Finance 
 Nominated Adviser and Joint Broker     0207 614 5900 
  Arden Partners plc            
  Paul Shackleton 
  Benjamin Onyeama-Christie 
 Joint Broker                           0203 657 0050 
  Turner Pope Investments (TPI) Ltd 
  Andy Thacker 
  James Pope 

Notes for Editors

Deltex Medical's technology

Deltex Medical's TrueVue System uses proprietary haemodynamic monitoring technology to assist clinicians to improve outcomes for patients as well as increase throughput and capacity for hospitals.

Deltex Medical has invested over the long term to build a unique body of peer-reviewed, published evidence from a substantial number of trials carried out around the world. These studies demonstrate statistically significant improvements in clinical outcomes providing benefits both to patients and to the hospital systems by increasing patient throughput and expanding hospital capacity.

The Group's flagship, world-leading, ultrasound-based oesophageal Doppler monitoring ("ODM") is supported by 24 randomised controlled trials conducted on anaesthetised patients. As a result, the primary application for ODM is focussed on guiding therapy for patients undergoing elective surgery.

During 2021, Deltex Medical's engineers and scientists carried out successful research in conjunction with the UK's National Physical Laboratory ("NPL"), which has enabled the Group's 'gold standard' ODM technology to be extended and developed so that it can be used completely non-invasively. This will significantly expand the application of Deltex Medical's technology to non-sedated patients. This new technological enhancement will substantially increase the addressable market for the Group's haemodynamic monitoring technologies and is complementary to the long-established ODM evidence base.

Our new non-invasive technology has potential applications for use in a number of healthcare settings, including:

-- Accident & Emergency for the rapid triage of patients, including the detection and diagnosis of sepsis, an important capability for patients presenting with COVID-19 symptoms;

-- in general wards to help facilitate a real-time, data-driven treatment regime for patients whose condition might deteriorate rapidly; and

-- in critical care units to allow regular monitoring of patients post-surgery who are no longer sedated or intubated.

One of the key opportunities for the Group in 2022 is positioning this new, non-invasive technology for use throughout the hospital. Our haemodynamic monitoring technologies provide clinicians with beat-to-beat real-time information on a patient's circulating blood volume and heart function. This information is critical to enable clinicians to optimise both fluid and drug delivery to patients.

Our business model is to drive the recurring revenues associated with the sale of single-use disposable ODM probes which are used in the TrueVue System and to complement these revenues with a new incremental revenue stream to be derived from our new non-invasive technology.

Both the existing single-use ODM probe and the new, non-invasive device connect to the same, next generation monitor which is due for launch in 2022. Monitors are sold or, due to hospitals' often protracted procurement times for capital items, loaned in order to encourage faster adoption of our technology.

Deltex Medical's customers

The principal users of our products are currently anaesthetists working in a hospital's operating theatre and intensivists working in ICUs. This customer profile will change as our new non-invasive technology is adopted by the market. In the UK we sell directly to the NHS. In the USA we sell directly to more than 30 major hospitals that appreciate the value of our evidence-based approach to haemodynamic management. We also sell through distributors in more than 40 countries in the European Union, Asia and the Americas.

Deltex Medical's objective

To see the adoption of our next generation TrueVue System, comprising both minimally invasive and non-invasive technologies, as the standard of care in haemodynamic monitoring for all patients from new-born to adult, awake or anaesthetised, across all hospital settings globally.

Visit us online for further information at

Chairman's Statement

Real-time oesophageal Doppler haemodynamic monitoring:

improves patient outcomes; increases hospital throughput


As expected, 2021 turned out to be a challenging year for Deltex Medical, although I can report that we are encouraged by the way that 2022 has started.

Our technology is principally used during elective surgery. Unfortunately, elective surgery was effectively closed for much of the year as health systems across the world continued to grapple with the impact of the COVID-19 ("Covid") pandemic whilst deciding how best to restart elective surgery. Intensive Care Units ("ICUs") once again filled up with mainly unvaccinated, extremely sick patients. Staff shortages compounded the provision-of-care challenges facing hospitals.

Although at the beginning of the pandemic, starting in late March 2020, there was an uptick in sales of the Group's haemodynamic monitoring technology into ICUs, this rapidly became dwarfed by the drop-off in the use of our products associated with the cessation of elective surgery in almost all hospitals in the world.

In all our markets there is now a large backlog of patients requiring elective surgical procedures. This represents a clinical and, increasingly, a political problem, particularly for government-funded healthcare systems. An NHS publication "Delivery plan for tackling the COVID-19 backlog of elective care" published on 8 February 2022 states that "Six million people are now on the waiting list, up from 4.4 million before the pandemic."

On 1 December 2021 the UK's National Audit Office published a report entitled: "NHS Backlog and waiting times in England". This report states that "Under two plausible scenarios, the elective care waiting list will be longer in 2025 than it is today." Further, this report suggests that under one of these scenarios the waiting list in March 2025 will contain 12.0 million patient pathways, compared to 5.8 million in September 2021.

The size and scale of the backlog means that hospitals and health systems should be looking to use our technology to help them rapidly reduce the elective surgery backlog and this represents a significant commercial opportunity for the Group. Conversely, the sheer size and scale of the backlog may also make it challenging to sell new technology into a stressed operating theatre environment, as clinicians are under acute pressure to work rapidly through operating lists. In addition, many hospitals have been slow at reopening access in the operating theatre to people not directly involved in the surgical process. This makes it more difficult for our clinical educators to provide clinical support to new clinicians who have been significantly less active in respect of elective surgery for the last two years.

While the environment starts to normalise, we will focus our commercial activities on hospital accounts that had previously adopted and used the Group's TrueVue Doppler technology in the operating theatre. In addition to driving back up usage rates from existing users, we will separately introduce a number of different initiatives to drive adoption of our new, non-invasive haemodynamic monitoring technology which we will be launching later this year. We believe that this new, broad application, non-invasive technology will, as well as being adopted by new users, help drive interest in, and usage of, our long-standing minimally invasive ODM technology. This is due to the new device allowing anaesthetists to quickly assess which of their patients will benefit from having the use of the advanced ODM technology.

The evidence showing that the use of our Doppler-based haemodynamic monitoring technology improves patient outcomes and increases hospital capacity (as a result of shorter patient length-of-stay) is strong. We believe that the next generation monitor which we will launch in 2022 and the new completely non-invasive device, which will also be available on this monitor, will represent a compelling solution for clinicians and hospital systems needing to handle their patient throughput more effectively.

Financial results

Group revenues for the year ended 31 December 2021 were GBP2.3 million (2020: GBP2.4 million) and reflect the impact of Covid on elective surgery. In 2021 the entire year's results were affected by the pandemic whereas in 2020 we had reasonable activity levels in the first quarter. Probe revenues declined by 9.6% to GBP1.9 million (2020: GBP2.1 million). Monitor revenues increased by 25% to GBP202,000 (2020: GBP161,000) reflecting improved trading in our International division in the year.

The consolidated gross margin in 2021 was 70% (2020: 68%). The slight increase in gross margin reflects a number of manufacturing efficiency savings that we were able to capture during the year.

Overheads were flat in the year totalling some GBP2.7 million (2020: GBP2.7 million, excluding exceptional costs of GBP232,000).

In the year the total value of UK and US government salary support schemes was GBP0.3 million (2020: GBP0.4 million).

Adjusted EBITDA for the year (comprising earnings before interest, tax, depreciation and amortisation, share-based payments, non-executive directors' fees, as well as any exceptional items) was a loss of GBP(0.5) million (2020: GBP(0.2) million).

Loss for the year was GBP(1.0) million (2020: GBP(0.8) million).

Cash at hand at 31 December 2021 was GBP0.4 million (2020: GBP0.9 million). This cash resource has since been supplemented by a fund raising of GBP1.4 million (gross) which was announced on 8 February 2022.

Business activities

Whilst our direct sales operations in the UK and the USA struggled to gain access to customers during the year as the majority of hospitals had put in place bans on visits by salespeople or clinical educators, our International division saw revenues grow by 40% to GBP926,000 (2020: GBP661,000). This growth helps to demonstrate the potential of, and associated opportunity with, our international network of some 40 distributors across the world.

During 2021 the Group's research and development team focussed on completing the development of our next generation monitor for launch in 2022. Launch of this monitor will provide us with immediate access to new potential revenue streams through sales of this updated device to existing users, as well as providing a platform for the introduction of our new non-invasive haemodynamic monitoring technology later this year.


On behalf of the Board, I would like to thank Deltex Medical's highly trained and dedicated employees, most of whom are based in the UK and the USA, for their continuing efforts and dedication in the very taxing environment which we saw throughout 2021. In these very difficult circumstances, our employees displayed great flexibility and fortitude, and remained responsive to our customers' wishes throughout the year.

Current trading and prospects

As access to hospitals improves for our direct sales forces in the UK and the USA then we expect our business to begin to normalise.

We also anticipate that our international business will continue to grow in 2022 and we have already announced a US$0.2 million order from a territory in the Americas which we expect will generate significant contracted single-use probe revenues this year.

Following the GBP1.4 million (gross) fund raising announced in February 2022, Deltex Medical, with the benefit of its grant awards, will have sufficient financial resources to complete the development of its next generation monitor and its new, broad application, non-invasive haemodynamic monitoring technology

Our initial focus is to drive activity levels back up to those achieved by the Group prior to the pandemic. Once attained, we believe that there is clear scope to grow the business, both in the UK, USA and in other international territories.

Nigel Keen


6 April 2022

Business Review


Deltex Medical is the world leader in highly accurate oesophageal Doppler monitoring ("ODM"), via its TrueVue platform, which allows real-time monitoring of a patient's haemodynamic status.

A substantial number of peer-reviewed, randomised controlled trials have shown that an ODM-driven haemodynamic protocol can result in statistically significant reductions in post-operative complications, resulting in lower costs for hospitals due to shorter patient length-of-stay. This is not only good for patients but also increases throughput and capacity for hospitals, which will be a key factor in the near term for reducing the backlog in elective surgery.

Deltex Medical's technology was originally developed in an ICU in London to assist with the treatment of acutely unwell critical care patients. Over time demand for the Group's high fidelity oesophageal Doppler-based haemodynamic monitoring technology has migrated from the ICU to the operating theatre, and particularly for elective surgery. Before the pandemic, approximately 80% of the Group's revenues were associated with elective surgical procedures in operating theatres. Accordingly, the cessation of elective surgery for much of 2021 was highly disruptive to Deltex Medical's commercial activities.

During 2021, our research and development team made impressive and substantial progress both in completing the development of our new, next generation TrueVue monitor and also in developing a complementary, non-invasive haemodynamic monitoring technology which leverages the extensive evidence base supporting the use of our existing ODM technology. The new device allows instantaneous non-invasive deployment anywhere in the hospital. This substantially broadens the potential applications, and hence addressable market size, for the Group's technology.

Our key challenge for 2022 is to ensure that, as hospitals open up and the volume of elective surgery increases, the Group is able to capitalise on these increased activity levels in operating theatres as well as capturing all the upside associated with our new non-invasive Doppler-based technology.


When Covid first emerged in 2020, the Group initially experienced increased demand for its TrueVue Doppler technology in ICUs, as clinicians worked to establish the optimal treatment protocols for severely sick Covid patients.

Over the last two years Covid treatment protocols have improved and the importance of haemodynamic monitoring as a part of optimal Covid treatment is now better understood. However, in developed countries the number of patients in ICUs has declined, in large part as vaccination rates have increased substantially, resulting in a decline in demand for the Group's oesophageal Doppler technology in ICUs for the treatment of ventilated Covid patients.

Around the world there is now a substantial backlog in elective surgical procedures as a result of the closure of operating theatres during the pandemic.

A chart published by the British Medical Association showed the increase in the NHS backlog of elective care from 4.4 million people at the start of the pandemic to 6.1 million in December 2021.

A second chart published by the National Audit office showed that under two plausible scenarios, the NHS backlog in March 2025 could be substantially higher than today, with one estimate putting the backlog as high as 12.0 million.

This backlog in elective care, which is a global phenomenon, represents a significant commercial opportunity for Deltex Medical as use of its TrueVue Doppler technology should result in greater patient throughput in respect of elective surgery, and hence increased hospital capacity.

One of the largest challenges that the Group, in common with most medical device companies, currently faces is that many hospitals around the world have restricted access to salespersons and clinical educators to help reduce the risk of the spread of Covid within hospitals.

Visits by Deltex Medical salespersons and clinical educators within the operating room environment results in appropriate levels of operating theatre staff trained in the use of ODM. The Group has internal studies which show that higher probe usage in these units is associated with recent visits by Deltex Medical employees. Conversely, it also has data which show that hospitals which have not been visited by a Deltex Medical employee for some time typically display reduced probe usage. As a result, one of the key challenges which the Group is focussing on this year is improving access for its direct sales force to hospitals in the UK and the USA.

The Group is considering a number of strategies to improve customer access, including possibly collaborating with larger groups which, as a result of their size and financial resources, have better reach and penetration into the operating theatre market.

Covid has also had a significant adverse effect on global supply chains, particularly in respect of semiconductors and raw materials. This has created issues for the Group's product development activities, and, in particular, contributed materially to the slippage of the launch of our next generation monitor from 2021 into 2022.

During 2021 the Group adopted a number of work-from-home protocols. Whilst working from home has had some advantages for some of our employees, it has also created challenges as the Group's research & development ("R&D") teams were forced to carry out complex development work remotely and without full access to Deltex Medical's research laboratories located in our headquarters in Chichester.

These Covid challenges should be seen in the context of the Group's pre-pandemic results when the Group had positive adjusted EBITDA of GBP0.4 million in 2019 and revenues nearly twice the 2021 level. (2021 revenues: GBP2.3 million; 2019: GBP4.3 million). Our primary focus is to return the business to these previously achieved activity levels, and then start to build profitable growth thereafter.

Product development and innovation

The ability to innovate and drive haemodynamic monitoring technology forward remains a key component of the Group's strategy.

The need for the new, next generation monitor has been apparent for some time. In 2021 a substantial proportion of our R&D activities were focussed on bringing this monitor to market. We anticipate launching the new, next generation monitor later this year.

Much of our product development work has been assisted by a number of competitively-won grant awards. For example, in 2021 the Group was notified of grant awards worth approximately GBP0.6 million (gross) (2020: nil), including a prestigious Smart Award from Innovate UK. Work eligible for the latest grant starts in April 2022.

One notable grant award related to collaborative work between Deltex Medical and the UK's National Physical Laboratory ("NPL") based in Teddington. This collaborative research work has enabled the Group to extend the application and utility of its oesophageal Doppler monitoring, including the development of a non-invasive device with broad utility.

Deltex Medical's oesophageal Doppler is classified as a minimally-invasive device; however, it still requires the insertion of a probe down the oesophagus of a sedated or anaesthetised patient. The requirement for the patient to be sedated has historically limited the application of our ODM technology. However, development work carried out in 2021 with NPL has enabled Deltex Medical to develop a new, non-invasive haemodynamic monitoring device which can be placed at the base of the patient's neck (the suprasternal notch) to generate real-time, highly accurate data on the haemodynamic status of the patient. This non-invasive device, which can provide clinicians with an instant measurement of a patient's haemodynamic status, will significantly expand the possible applications and size of the addressable market for the Group. In addition to adoption by new users, this non-invasive device should help drive interest in, and usage of, our long-standing minimally invasive ODM technology as the use of the new device will allow anaesthetists to assess which of their patients will benefit from the more intense monitoring available through the use of the TrueVue system.

Market developments

The majority of the Group's activities are currently centred around the treatment of human patients within the hospital setting. However, we have also been developing our haemodynamic monitoring platform for use in veterinary applications in the treatment of small animals in a number of different sites around the world. Although the size of this market is currently quite small, we believe that it has the potential to grow. Accordingly, we are working closely with, and supporting technologically, a number of key opinion leading veterinarians who are interested in the application of the Group's TrueVue Doppler technology in the treatment of sick animals.


Deltex Medical designs and manufactures Class II medical devices which it sells around the world. As a result, its business activities can be significantly affected by changes to regulations. At any time there are typically a number of regulatory changes under consideration from the regulatory bodies governing such devices.

Fortunately, to date the effect on the Group from Brexit has been relatively limited, although we have been forced to register our products in Spain, despite having sold into the Spanish market for more than 15 years. The post-Brexit regulatory regime is still evolving and we keep actual or prospective changes in regulations under close review.

In Europe we are currently in the process of transitioning from the Medical Device Directive to the Medical Device Regulation ("MDR"). The European MDR comprises a new set of regulations that govern the production and distribution of medical devices in Europe. Compliance with this new regulation is mandatory for medical device companies that want to sell their products into the European marketplace.

There are certain provisions within the MDR which, if enforced in a timely manner, could help Deltex Medical. For example, there is an increasing requirement for manufacturers of medical devices to generate their own body of efficacy data, and not to rely on third party data in regulatory submissions. Deltex Medical benefits from a substantial body of published literature relating to the use of its technology which shows statistically significant effects associated with improving patient outcomes and reducing patient length-of-stay. As the MDR comes into effect we anticipate that the value and utility of the Group's own scientific evidence base should continue to increase.

Three principal divisions: UK, USA and International

Deltex Medical structures its commercial activities around three divisions: the UK; the USA and International.

Although in 2021 access to customer accounts was extremely limited, we have had some notable successes with long-standing customers in both the UK and the USA. For example, at some institutions we have been able to stay in close contact remotely with anaesthetists, which has resulted in a steady stream of probe usage, albeit at much lower levels than before the pandemic started. However, it is clear that where our sales personnel are unable to obtain meaningful access to anaesthetists, or other appropriate operating theatre staff, then probe usage typically declines.

Over recent months there have been encouraging signs where we have been able to start to re-engage with operating theatre personnel in a number of hospitals. As hospitals open up again, we plan to expand the size of our sales team in the USA and focus on our existing accounts, which should help us to start to drive up high margin single-use probe revenues.

The International division performed well in 2021 with growth of 40% to GBP0.9 million (2020: GBP0.7 million). The Group's distributor in France achieved strong activity levels, partly as a result of a long-term contract with the Association of Public Hospitals in Paris. In January 2022 one of the Group's distributors in the Americas won contracts worth some US$0.2 million which combined the sale of monitors with predetermined and contracted probe sales to a number of public hospitals.

Not all of the Group's international distributors performed strongly during the pandemic. Many of these distributors comprise businesses focussed on selling equipment and consumables into operating theatres which, similar to Deltex Medical, have seen much lower activity levels in 2021.


The Covid pandemic is transitioning to becoming endemic in the community and the elevated vaccination rates around the world mean that hospitals are now starting to open up access to suppliers, and their sales teams, once again. They are also starting to work hard to reduce their respective backlogs in elective surgery.

We made a number of important steps forward with our product development programmes in 2021 and look forward to the launch this year of the next generation monitor as well as the finalisation of the new, non-invasive device with substantially larger addressable market size.

In February 2022 we announced a GBP1.4 million (gross) fund raising which will, among other things, enable us to take advantage of the substantial grant finance that totalled GBP0.6 million (gross) that we were awarded last year.

Our key challenge for 2022 is to release the next generation TrueVue monitor, along with our new non-invasive ultrasound device, and see elective surgery activity levels return to the levels that were being achieved before the Covid pandemic became evident.

Andy Mears

Chief Executive

6 April 2022

Consolidated statement of comprehensive income 
For the year ended 31 December 2021 
                                                                       2021                2020 
                                                     Note             GBP'000               GBP'000 
 --------------------------------------------------------  --------------------  ------------------- 
   Revenue 3                                                         2,259                 2,398 
   Cost of sales 4                                                     (684)                 (757) 
 --------------------------------------------------------  --------------------  ------------------- 
   Gross profit                                                      1,575                 1,641 
   Administrative expenses                                          (1,585)               (1,472) 
   Sales and distribution expenses                                     (957)                (964) 
   Research and Development, Quality and Regulatory                    (207)                 (246) 
   Impairment reversal on trade receivables 24                           -                     11 
   Exceptional costs 9                                                   -                   (232) 
 --------------------------------------------------------  --------------------  ------------------- 
   Total costs 4                                                    (2,749)               (2,903) 
 --------------------------------------------------------  --------------------  ------------------- 
   Other operating income 10                                            312                      469 
 --------------------------------------------------------  --------------------  ------------------- 
   Other gain 7                                                          57                     171 
 --------------------------------------------------------  --------------------  ------------------- 
   Operating loss                                                      (805)                   (622) 
 --------------------------------------------------------  --------------------  ------------------- 
   Finance costs 6                                                     (173)                 (172) 
 --------------------------------------------------------  --------------------  ------------------- 
   Loss before taxation                                                (978)                 (794) 
   Tax credit on loss 7                                               12                       9 
 --------------------------------------------------------  --------------------  ------------------- 
   Loss for the year                                                   (966)                 (785) 
 --------------------------------------------------------  --------------------  ------------------- 
   Other comprehensive expense 
   Items that may be reclassified to profit or 
   Net translation differences on overseas subsidiaries                 (2)                      (6) 
 --------------------------------------------------------  --------------------  ------------------- 
   Other comprehensive expense for the year, 
    net of tax                                                          (2)                      (6) 
 --------------------------------------------------------  --------------------  ------------------- 
   Total comprehensive loss for the year                               (968)                 (791) 
 --------------------------------------------------------  --------------------  ------------------- 
     Total comprehensive loss for the year attributable 
   Owners of the Parent                                                (969)                 (804) 
   Non-controlling interests                                             1                        13 
 --------------------------------------------------------  --------------------  ------------------- 
                                                                       (968)                 (791) 
 --------------------------------------------------------  --------------------  ------------------- 
   Loss per share - basic and diluted 11                                (0.17p)              (0.15p) 
 --------------------------------------------------------  --------------------  ------------------- 

Consolidated balance sheet

As at 31 December 2021

                                                 2021              2020 
                                              GBP'000             GBP'000 
-------------------------------------  ----  --------  ------------------ 
  Non-current assets 
  Property, plant and equipment          12       264                 305 
  Intangible assets                      13     3,135             2,554 
  Financial assets at amortised cost     16       157                 153 
-------------------------------------  ----  --------  ------------------ 
  Total non-current assets 
   Current assets                               3,556             3,012 
  Inventories                            15       796                 895 
  Trade receivables                      16       455               576 
  Financial assets at amortised cost     16        15                  15 
  Other current assets                   16        91                 122 
  Current income tax recoverable                   69                  61 
  Cash and cash equivalents                       413                 853 
-------------------------------------  ----  --------  ------------------ 
  Total current assets                          1,839             2,522 
-------------------------------------  ----  --------  ------------------ 
  Total assets                                  5,395             5,534 
-------------------------------------  ----  --------  ------------------ 
   Current liabilities 
  Borrowings                             18     (702)               (159) 
  Trade and other payables               18   (1,478)             (1,416) 
-------------------------------------  ----  --------  ------------------ 
  Total current liabilities                   (2,180)             (1,575) 
-------------------------------------  ----  --------  ------------------ 
  Non-current liabilities 
  Borrowings                             18   (1,028)               (993) 
  Trade and other payables               18     (228)               (274) 
  Provisions                             20      (57)                (51) 
-------------------------------------  ----  --------  ------------------ 
  Total non-current liabilities               (1,313)             (1,318) 
-------------------------------------  ----  --------  ------------------ 
  Total liabilities                           (3,493)             (2,893) 
-------------------------------------  ----  --------  ------------------ 
  Net assets                                    1,902             2,641 
-------------------------------------  ----  --------  ------------------ 
  Share capital                          21     5,849             5,773 
  Share premium                          26    33,502           33,444 
  Capital redemption reserve             26    17,476           17,476 
  Other reserve                          26       573                 505 
  Translation reserve                    26       133                 135 
  Convertible loan note reserve          26        82                  82 
  Accumulated losses                     26  (55,588)            (54,648) 
-------------------------------------  ----  --------  ------------------ 
  Equity attributable to owners of 
   the Parent                                   2,027             2,767 
  Non-controlling interests                     (125)               (126) 
-------------------------------------  ----  --------  ------------------ 
  Total equity                                  1,902             2,641 
-------------------------------------  ----  --------  ------------------ 

Consolidated statement of changes in equity

For the year ended 31 December 2021

                                                         Capital                       Convertible                                              Non- 
                       Share           Share             redemption        Other         loan note   Translation   Accumulated    Total         controlling 
                       capital         premium           reserve           reserve         reserve       reserve        losses                  interest 
                       GBP'000         GBP'000              GBP'000        GBP'000         GBP'000       GBP'000       GBP'000  GBP'000             GBP'000 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 
 Balance at 1 
  2021                   5,773          33,444               17,476            505              82           135      (54,648)    2,767         (126) 2,641 
 Loss for the 
  period                     -               -                    -              -               -             -         (967)    (967)             1 (966) 
  income for the 
  period                     -               -                    -              -               -           (2)             -      (2)               - (2) 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 
  income for 
  year                       -               -                    -              -               -           (2)         (967)    (969)             1 (968) 
 owners of the 
 Shares issued 
  during the 
  year                      76              58                    -              -               -             -             -      134               - 134 
  share- based 
  payment                    -               -                    -             95               -             -             -       95                - 95 
 Transfers                   -               -                    -           (27)               -             -            27        -                 - - 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 
 Balance at 
  31 December 
  2021                   5,849          33,502               17,476            573              82           133      (55,588)    2,027         (125) 1,902 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 

Consolidated statement of changes in equity

For the year ended 31 December 2020

                                                         Capital                       Convertible                                              Non- 
                       Share           Share             redemption        Other         loan note   Translation   Accumulated    Total         controlling 
                       capital         premium           reserve           reserve         reserve       reserve        losses                  interest 
                       GBP'000         GBP'000              GBP'000        GBP'000         GBP'000       GBP'000       GBP'000  GBP'000             GBP'000 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 
 Balance at 1 
  2020                   5,249          33,230               17,476            439              82           141      (53,823)    2,794         (139) 2,655 
 Loss for the 
  period                     -               -                    -              -               -             -         (798)    (798)            13 (785) 
  income for the 
  period                     -               -                    -              -               -           (6)             -      (6)               - (6) 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 
  income for 
  year                       -               -                    -              -               -           (6)         (798)    (804)            13 (791) 
 owners of the 
 Shares issued 
  during the 
  year                     524             217                    -              -               -             -             -      741               - 741 
 Issue expenses              -             (3)                    -              -               -             -             -      (3)               - (3) 
  share- based 
  payment                    -               -                    -             39               -             -             -       39                - 39 
 Transfers                   -               -                    -             27               -             -          (27)        -                 - - 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 
 Balance at 
  31 December 
  2020                   5,773          33,444               17,476            505              82           135      (54,648)    2,767         (126) 2,641 
----------------  ------------  --------------  -------------------  -------------  --------------  ------------  ------------  -------  ------------------ 
Consolidated statement of cash flows 
for the year ended 31 December 2021 
                                                                   2021                  2020 
                                                                  GBP'000                GBP'000 
---------------------------------------------------  --------------------  --------------------- 
  Cash flows from operating activities 
  Loss before taxation                                              (978)                  (794) 
  Adjustments for: 
  Net finance costs                                                173                       172 
  Depreciation of property, plant and equipment                        74                    103 
  Amortisation of intangible assets                                    40                     40 
  Write off of research and development projects 
   not taken forward                                                  -                      222 
  Modification gain on convertible loan note                            -                  (119) 
  Share-based payment expense                                          95                     39 
  Other tax income                                                   (57)                   (52) 
  Effect of exchange rate fluctuations                                (2)                    (6) 
---------------------------------------------------  --------------------  --------------------- 
                                                                    (655)                  (395) 
  Decrease in inventories                                              89                     13 
  Decrease in trade and other receivables                             148                    680 
  Increase/(decrease) in trade and other payables                     191                  (303) 
  Increase/(decrease) in provisions                                     6                   (11) 
---------------------------------------------------  --------------------  --------------------- 
  Net cash used in operations                                       (221)                   (16) 
  Interest paid                                                     (131)                  (132) 
  Income taxes received                                                61                     80 
---------------------------------------------------  --------------------  --------------------- 
  Net cash used in operating activities                             (291)                   (68) 
  Cash flows from investing activities 
  Purchase of property, plant and equipment                          (23)                    (6) 
  Capitalised development expenditure (net 
   of grants)                                                       (621)                  (165) 
---------------------------------------------------  --------------------  --------------------- 
  Net cash used in investing activities                             (644)                  (171) 
  Cash flows from / (used in) financing activities 
  Issue of ordinary share capital                                       -                    253 
  Expenses in connection with share issue                               -                    (3) 
  Net movement in invoice discount facility                            43                   (23) 
  Standby loan facility drawdown                                      500                      - 
  Principal lease payments                                           (41)                   (37) 
---------------------------------------------------  --------------------  --------------------- 
  Net cash generated from financing activities                        502                    190 
---------------------------------------------------  --------------------  --------------------- 
  Net decrease in cash and cash equivalents                         (433)                   (49) 
  Cash and cash equivalents at beginning of 
   the period                                                         853                    908 
  Exchange loss on cash and cash equivalents                          (7)                    (6) 
---------------------------------------------------  --------------------  --------------------- 
  Cash and cash equivalents at end of the 
   period                                                             413                    853 
---------------------------------------------------  --------------------  --------------------- 

1. Nature of the financial information

This Results Summary containing condensed financial information for the year ended 31 December 2021 should be read in conjunction with the Deltex Medical Group Plc's Annual Report & Accounts 2021 which were in accordance with UK-adopted International Accounting Standards. The consolidated financial statements have been prepared under the historical cost convention and on a going concern basis.

Financial information contained in this document does not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006 ('the Act'). The statutory accounts for the year ended 31 December 2020 have been filed with the Registrar of Companies and those for the year ended 31 December 2021 will be filed with the Registrar of Companies following the Annual General Meeting. The report of the independent auditor on those statutory accounts was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under section 498(2) or (3) of the Act. The report for year ended 31 December 2020 of the independent auditor on those statutory accounts was unqualified and did not contain a statement under section 498(2) or (3) of the Act. The report drew attention by way of emphasis to the matters set out in the going concern accounting policy regarding the inherent uncertainties regarding Covid-19 and the impact on demand for the Group's products. The auditor's opinion was not modified in respect of these matters.

2. Accounting policies

The Group's principal accounting policies can be found on pages 47 to 49 of the Group's Annual Report & Accounts 2021.

Going concern

The Directors have reviewed detailed budgets and forecasts until 30 June 2023, which take into account, among other things, the possible continued effects of Covid on the Group's business. This review indicates that the Group is expected to continue trading as a going concern based on projected net cash flows derived from sales of the Group. In February 2022, the Group raised GBP1.4 million (gross) through a share subscription which provided additional cash resources to the Group. In addition, the Group agreed a 12 month extension to the standby loan facility which is now repayable on or before 31 December 2023.

The Directors consider that they have reasonable grounds to believe that the Group will have adequate resources to continue in operational existence for the foreseeable future and it is therefore appropriate to prepare the financial statements on the going concern basis.

3. Revenue

For the year ended 31 December 2021

                                   Direct markets                        Indirect markets 
                       Probes            Monitors           Other         Probes Monitors       Other          Total 
                       GBP'000            GBP'000           GBP'000         GBP'000 GBP'000      GBP'000     GBP'000 
------------------  ----------  -----------------  ------------------  --------------------  -----------  ---------- 
  UK                       524                 60                  86                   - -            -         670 
  USA                      561                 55                  47                   - -            -         663 
  France                     -                  -                   -                489 29            8         526 
  Scandinavia                -                  -                   -                 105 -            2         107 
  South Korea                -                  -                   -                 134 -            2         136 
  Portugal                   -                  -                   -                  35 -            -          35 
  Other countries           10                  -                   -                 53 58            1         122 
------------------  ----------  -----------------  ------------------  --------------------  -----------  ---------- 
                         1,095                115                 133                816 87           13       2,259 
------------------  ----------  -----------------  ------------------  --------------------  -----------  ---------- 

For the year ended 31 December 2020

                                   Direct markets                        Indirect markets 
                       Probes            Monitors           Other         Probes Monitors       Other          Total 
                       GBP'000            GBP'000           GBP'000         GBP'000 GBP'000      GBP'000     GBP'000 
------------------  ----------  -----------------  ------------------  --------------------  -----------  ---------- 
  UK                       652                102                  83                   - -            -         837 
  USA                      858                 16                  26                   - -            -         900 
  France                     -                  -                   -                 170 -           10         180 
  Scandinavia                -                  -                   -                  95 -            2          97 
  South Korea                -                  -                   -                 159 -            1         160 
  Portugal                   -                  -                   -                  86 -            -          86 
  Other countries           15                 32                   -                 78 11            2         138 
------------------  ----------  -----------------  ------------------  --------------------  -----------  ---------- 
                         1,525                150                 109                588 11           15       2,398 
------------------  ----------  -----------------  ------------------  --------------------  -----------  ---------- 

The Group's revenue disaggregated between the sale of goods and the provision of services is set out below. All revenues from the sale of goods are recognised at a point in time; maintenance income is recognised over time.

                          2021            2020 
                       GBP'000             GBP'000 
--------------------  --------  ------------------ 
 Sale of goods           2,192               2,338 
 Maintenance income         67                  60 
--------------------  --------  ------------------ 
                         2,259               2,398 
--------------------  --------  ------------------ 

The following table provides information about trade receivables and contract liabilities from contracts with customers. There were no contract assets at either 31 December 2021 or 31 December 2020.

                                              31 December  31 December 
                                                     2021         2020 
                                                  GBP'000      GBP'000 
--------------------------------------------  -----------  ----------- 
  Trade receivables which are in 'Trade and 
   other receivables'                                 455          576 
  Contract liabilities                               (57)         (58) 
--------------------------------------------  -----------  ----------- 

The following aggregated amounts of transaction prices relate to the performance obligations from existing contracts that are unsatisfied or partially unsatisfied as at 31 December 2021:

                                      2022                2023                2024               Total 
                                       GBP'000           GBP'000             GBP'000              GBP'000 
-------------------------  -------------------  ----------------  ------------------  ------------------- 
  Revenue expected to be 
   recognised                             36             7                  14                         57 
-------------------------  -------------------  ----------------  ------------------  ------------------- 

Revenue recognised in 2021 which was included in contract liabilities at 31 December 2020 amounted to GBP54,000. Revenue recognised in 2020 included in contract liabilities at 31 December 2019 amounted to GBP46,000.

4. Dividends

The directors cannot recommend payment of a dividend (2020: nil).

5. Basic and diluted loss per share

The loss per share calculation is based on the loss of GBP967,000 and the weighted average number of shares in issue of 580,712,339. For 2020, the loss per share calculation is based on the loss of GBP798,000 and the weighted average number of shares in issue of 526,448,659. While the Group is loss-making, the diluted loss per share and the loss per share are the same.

6. Subsequent events

On 8 February 2022, the Group raised GBP1,396,000, before expenses, through subscription for 111,720,000 new Deltex Medical ordinary shares at a price of 1.25 pence per share.

Also on 8 February 2022, the standby loan facility which was set up on 20 September 2021, was extended for an additional year, and is repayable in full on or before 31 December 2023. As already noted, the facility is provided by Imperialise Limited, a company controlled by Nigel Keen. The interest rate remains unchanged on the facility at 8% per annum, and is unsecured.

Distribution of Annual Report and Accounts

The Group will also shortly be posting a copy of the Annual Report and Accounts for the year ended 31 December 2021 to shareholders, together with a Notice of Annual General Meeting to be held at 11.00 am on 18 May 2022 at the offices of DAC Beachcroft LLP, 25 Walbrook, London, EC4N 8AF.

A copy of the Annual Report and Accounts and of the Notice of Annual General Meeting will also shortly be available from the Company's website at

, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

April 07, 2022 02:01 ET (06:01 GMT)

1 Year Deltex Medical Chart

1 Year Deltex Medical Chart

1 Month Deltex Medical Chart

1 Month Deltex Medical Chart
ADVFN Advertorial
Your Recent History
Deltex Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220628 05:46:00